Unidade de Investigación en Cardioloxía Celular e Molecular
C.C.M.
![Foto de Unidade de Investigación en Cardioloxía Celular e Molecular](/img/grupo.png)
![Foto de Brigham and Women's Hospital](/img/noimage_org.png)
Brigham and Women's Hospital
Boston, Estados UnidosPublicacións en colaboración con investigadores/as de Brigham and Women's Hospital (9)
2019
-
Dapagliflozin and cardiovascular outcomes in type 2 diabetes
New England Journal of Medicine, Vol. 380, Núm. 4, pp. 347-357
-
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628
-
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
The Lancet, Vol. 394, Núm. 10204, pp. 1169-1180
2018
-
Alirocumab and cardiovascular outcomes after acute coronary syndrome
New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107
2017
-
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention
Journal of the American College of Cardiology, Vol. 69, Núm. 2, pp. 176-185
-
Cardiovascular efficacy and safety of bococizumab in high-risk patients
New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539
-
Evolocumab and clinical outcomes in patients with cardiovascular disease
New England Journal of Medicine, Vol. 376, Núm. 18, pp. 1713-1722
2015
-
Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation?: The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation
Circulation: Cardiovascular Quality and Outcomes, Vol. 8, pp. S12-S20
2013
-
Edoxaban versus warfarin in patients with atrial fibrillation
New England Journal of Medicine, Vol. 369, Núm. 22, pp. 2093-2104